July 8, 2014
GREENWICH, CT and LONG CRENDON, UK — Great Point Partners, a Greenwich-based health care investment firm, today announced a growth recapitalization of Softbox Systems, Ltd. (“Softbox”). Softbox is a leading provider of temperature controlled packaging (“TCP”) solutions for the biotechnology and pharmaceutical industries. The Company’s products play a critical role in maintaining the integrity of temperature-sensitive drugs, vaccines and active pharmaceutical ingredients (“API”) during the distribution process.
The investment will enable Softbox to expand its global geographic footprint, diversify its product offering, and continue to invest in superior customer service for its clients.
“We are very excited about the opportunity to partner with Great Point. We were impressed with their rolodex of customer relationships in the biotechnology industry, the robust acquisition pipeline they had developed, and their deep industry knowledge. We are confident that their resources will allow us to achieve a higher level of growth by tapping into new markets, broadening our product line, and expanding our customer base. We believe that we will solidify our market leading position in this rapidly growing industry,” said Richard Jones, Chief Executive Officer of Softbox.
“Softbox presented a compelling opportunity to invest in a global leader in the market of TCP solutions for the biopharmaceutical industry,” said Adam B. Dolder, Managing Director at Great Point Partners. “Management’s deep domain knowledge and commitment to innovation of new solutions for their customers have created a unique platform in the industry. Richard and Edwin Tattam, Founder, have developed a company with extraordinary customer satisfaction and durable, long-term relationships with its customers.”
As part of Great Point’s investment, Dr. Jeffrey R. Jay and Noah F. Rhodes, III will join Mssrs. Tattam, Jones and Dolder on Softbox’s Board of Directors. In addition, Dr. Bernard Hampl of Great Point Partners CEO Advisory Board will also serve as Co-Chairman of the Board along with Mr. Tattam. Dr. Hampl is also Co-Chairman of the Board of Cytovance Biologics and a Director of Chemwerth Inc., a leading API provider to the pharmaceutical industry. Previously, Dr. Hampl was CEO of Eon Labs from 1996 to 2005 until the acquisition by Novartis at which time he became the CEO of the Sandoz US-division of Novartis.
About Softbox Systems, Ltd.
Softbox was founded in 1995 in order to take advantage of increasing focus on temperature controlled packaging by the biopharmaceutical industry and global regulatory bodies. The company currently supplies a line of packaging solutions (“PolyBox”, “TempCell”, “SilverPod”, etc.), and currently serves more than half of the world’s 50 largest pharmaceutical companies. Softbox has a global presence, with headquarters in the United Kingdom, and additional locations in the United States, India, Singapore, and Australia. Learn more at www.softboxsystems.com.
About Great Point Partners
Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $800 million of equity capital under management and 26 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million in commitments. Great Point manages capital in private (GPP I, $156 million, and GPP II) and public (BMVF, approximately $370 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including biologics and pharmaceutical infrastructure, devices and diagnostics, health care services, hospital outsourcing, information technology, and specialty pharmaceuticals. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203-971-3300 or www.gppfunds.com.
This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.